In total, FABP7 positives were detected in 14 out of the 205 breast non-apocrine carcinomas (6,79%): 8 out of the 42 TNBCs (19,04%); 1 out of the 103 Luminal A subtypes (0,97%); in none out of the 17 Luminal B (0%) and in 5 out of the 43 HER2+ (11,62%). Here, ERBB2 is linked to apocrine adenocarcinoma.